Introduction
New approaches in vaccines, such as DNA vaccines, new combination vaccines, new formulations, novel delivery routes, new adjuvants are being explored. In the last three years the cancer vaccine industry has reshaped itself quite considerably. The number of cancer vaccine players has rather decreased than increased, through operational re-prioritizations, M&As and fall outs.
Scope of this report
- In-depth competitive landscape assessment of the cancer vaccine market
- Tumor antigen discovery and technologies surrounding it
- Thorough review of immunomodulating strategies and adjuvants
- Thorough review of cancer vaccine delivery and technologies surrounding it
- Progress analysis of six major cancer vaccine indications, including players, drugs, clinical progress and pitfalls
Research and analysis highlights
Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications.
Key reasons to read this report
- Understand the clinical and strategic challenges to the commercialization of cancer vaccines
- Assess opportunities and risks for the continued development of cancer vaccines in six major cancer indications.
- Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development
1 Executive Summary
2 Cancer Highlights
3 Methodology
4 4.1 List of Boxes
4.2 List of Figures
4.3 List of Tables
5 Vaccine Strategies: Challenges & Opportunities
6 Competitive Landscape in Cancer Vaccines
6.1 Countries & Players: Who are In the Lead?
6.1.1 Top 10 Players Constitute Up to One Third of R&D: Big Pharma Not Included!
6.1.2 Approved Cancer Vaccine Drugs: Performance
6.2 Deals & Alliances in Cancer Vaccines
6.2.1 Recent Mergers & Acquisitions in Cancer Vaccines
6.2.2 Deals in Prostate Cancer
6.2.3 Deals in Breast Cancer
6.2.4 Deals in Leukemia & Lymphoma
6.2.5 Drug Delivery Deals in Cancer Vaccines
6.2.6 Adjuvant Deals
7 Tumor Antigens
7.1 Tumor Antigens: General Comments
7.2 Antigen Discovery
7.2.1 Classical Immunology Approach
7.2.2 The Reverse Immunology Approach
7.2.3 Company Platforms
7.2.3.1 Epitope Identification System - EIS®
7.2.3.2 EPIQUEST system
7.2.3.3 MolecularBreeding™ & MaxyScan™
7.2.3.4 ProtEx™ technology
7.2.3.5 Rapid Identification of Alternative Splicing (RIAS) System
7.2.3.6 SMARTOMICS™
7.3 Specific Antigen Processing Technologies Increasing Antigen Presentation
8 Immunomodulators & Adjuvants in Cancer Vaccines
8.1 Overview
8.2 Cytokines
8.2.1 Vaccines in Combination with Interleukin-2
8.2.2 Tumor Necrosis Factor
8.2.3 Interferons
8.3 Adjuvants
8.4 Other Immunomodulating Strategies
8.4.1 An Immune Response Modifying Protein
8.4.2 Immunostimulatory DNA
8.4.3 Ex Vivo Stimulated Immune Cells
8.4.4 Fusion Protein Gain Potent Immune Response
8.4.5 Macrophage and Natural Killer Cells Activation
8.4.6 Selective Suppression of the Immune System to An Antigen
8.4.7 TAP Technology
9 Cancer Vaccine Delivery
9.1 Viral Delivery
9.1.1 Introduction
9.1.2 Viral Constructs Put into Use
9.1.2.1 Replicon-based RNA and DNA vaccines
9.1.2.1.1 The Alphavaccine Platform System - ArV™
9.1.2.1.2 MVA-BN
9.1.2.2 Retroviruses
9.1.2.2.1 The SDSV-platform
9.1.2.3 Lentivirus
9.1.2.3.1 LentiPak™
9.1.2.3.2 LentiVector™/ pEGASUS™
9.1.2.4 Adenoviruses
9.1.2.4.1 Failed Adenovirus Delivery Platforms
9.1.2.4.2 GVAX
9.1.2.4.3 TNFerade™
9.1.2.4.4 INGN-225
9.1.2.5 Adeno-associated viruses
9.1.2.5.1 Failed AAV Delivery Platforms
9.1.2.5.2 Genzyme Acquires AAV vector Technology
9.1.2.5.3 MediGene’s AAV Platform
9.1.2.6 Herpes Simplex Viruses
9.1.2.6.1 DISC-HSV
9.1.2.6.2 ImmunoVEX
9.1.2.7 Poxviruses
9.1.2.7.1 Hi-8™ PrimeBoost™ platform
9.1.2.7.2 PROSTVAC-VF
9.1.2.7.3 Transgene’s MVA Platform
9.1.2.7.4 TroVax
9.1.2.8 Other Poxvirus Systems
9.1.2.9 Baculovirus
9.1.2.9.1 Chimeric virus -like particles (CVLPs)
9.2 Bacterias
9.3 Cell Therapy: Dendritic-cell Based & Cancer-Cell Based Therapies
9.3.1 Introduction
9.3.2 Cell Therapy Strategies
9.3.2.1 Processed Tumor Cells
9.3.2.2 Lysed Tumor Cell Line
9.3.2.3 The Dendritic Cell Strategy that Didn’t Work Out
9.3.2.4 HSPs
9.3.2.5 Provenge™
9.3.2.6 Dendritophages
9.3.2.7 Cell-targeting Antibodies
9.3.2.8 Increase Dendritic Cell Number
9.3.2.9 DCVax®
9.3.2.10 ACTIVATE™
9.4 Synthetic Delivery Systems & Strategies
9.4.1 Introduction
9.4.2 Biotransport™
9.4.3 Biotype®vector
9.4.4 DNAVax Gene Delivery System
9.4.5 FusitAb™
9.4.6 GeneDrug™
9.4.7 Molecular Conjugates
9.4.8 Naked DNA Delivery
9.4.9 PVLP Technology
9.4.10 Sphingosomal Drug Delivery Technology
9.4.11 STEALTH
9.4.12 Failed Liposomal Systems
10 Non-Antibody Based Vaccines in Development: By Major Indications
10.1 General Oncology Overview
10.2 Progress Analysis – Melanoma
10.3 Progress Analysis – Breast Cancer
10.4 Progress Analysis – Prostate Cancer
10.5 Progress Analysis – Lung Cancer
10.6 Progress Analysis – Colorectal Cancer
10.7 Progress Analysis – Cervical Cancer
11 Disclaimer
16H11.1 Liability
17H11.2 Completeness
18H12 Drug Index
19H13 Company Index
4.1 List of Boxes
120HBox 1: Mechanisms Which Tumor Cells Use to Evade an Immune Reaction
121HBox 2: M-VAX – Business & Market Bakground
12HBox 3: Gardasil: Business & Market Background
123HBox 4: TNF in Cancer Treatments
4.2 List of Figures
124HFigure 1: Top 10 Countries in Cancer Vaccine Research
125HFigure 2: Top 10 Companies’ Clinical Trial Progress in Cancer Vaccine
126HFigure 3: 2003-2005 Deals & Alliances in Cancer Vaccine
127HFigure 4: Distribution of Cancer Vaccine Trials in Melanoma
128HFigure 5: Distribution of Cancer Vaccine Trials in Breast Cancer
129HFigure 6: Distribution of Cancer Vaccine Trials in Prostate Cancer
130HFigure 7: Distribution of Cancer Vaccine Trials in Lung Cancer
131HFigure 8: Distribution of Cancer Vaccine Trials in Colorectal Cancer
132HFigure 9: Distribution of Cancer Vaccine Trials in Cervical Cancer
4.3 List of Tables
13HTable 1: Companies with Cancer Vaccine Drugs on Market
134HTable 2: Antigen Classification
135HTable 3: Platforms Used to Improve Antigen Presentation
136HTable 4: Cancer Vaccines in Clinical Trials in Combination with Interleukin-2
137HTable 5: Adjuvants in Cancer Vaccines
138HTable 6: Synthetic Delivery Systems Deployed in Cancer in General and Cancer Vaccines in Particular
Table 7 Top 10 Cancer Indications in Non-Antibody Based Cancer Vaccines
Table 8: Discountinued Phase I to Phase III Cancer Vaccine Drugs
Table 9: List of Phase I to Phase III Cancer Vaccines in Development for Melanoma
Table 10: List of Phase I to Phase III Cancer Vaccines in Development for Breast Cancer
Table 11: List of Phase I to Phase III Cancer Vaccines in Development for Prostate Cancer
Table 12: List of Phase I to Phase III Cancer Vaccines in Development for Lung Cancer
Table 13: List of Phase I to Phase III Cancer Vaccines in Development for Colorectal Cancer
Table 14: List of Phase I to Phase III Cancer Vaccines in Development for Cervical Cancer
Other selected research from the 'Cancer Highlights' category:
A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Other selected research from the 'Triple Analysis' category:
Triple Analysis: Leukemia, Melanoma and Apoptosis
Triple Analysis: Apoptosis, Cancer Vaccines and Peptides
Other selected research from the 'Oncology' category:
Triple Analysis: Colorectal Cancer, Melanoma and Protein Kinase Inhibitors
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Other selected research from the 'Immunomodulators' category:
Cancer Vaccines Drug Pipeline Update 2012
Cytokine Therapy in Oncology Drug Pipeline Update 2012
Other selected research from the 'Vaccines' category:
European Vaccine Markets
What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline